Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the amount of capital funding which will be allocated to each NHS trust in London in each year between 2019 and 2022.
Answered by Stephen Hammond
The Department provides some specific central support in the form of capital loans and public dividend capital. The details of all financial assistance provided by the Department to individual National Health Service trusts and foundation trusts, including capital loans and public dividend capital, under section 40 of the National Health Service Act 2006 are published annually alongside the Department’s Annual Report and Accounts.
The largest centrally allocated capital programme over the period to 2022 is the sustainability and transformation partnerships (STP) capital programme. The following table shows the announced value of capital investment in STP schemes for London NHS trusts. The breakdown of funding in individual years will be determined - once they complete the standard full business case process.
Lead organisation | STP Scheme | Capital from STP Funding to 2022/23 (£000) |
Barnet, Enfield and Haringey Mental Health Trust | Children and Adolesent Mental Health Service (CAMHS) Tier 4. 3 new beds | 300 |
Camden and Islington NHS Foundation Trust | St Pancras - transformation of mental health and substance misuse services | 86,0001 |
Central and North West London Foundation Trust | CAMHS Tier 4. Kingswood Hospital. Five additional beds for people with learning difficulties/autistic spectrum disorders | 2,090 |
Central and North West London Foundation Trust | CAMHS Tier 4. 12 additional beds | 2,100 |
Central and North West London NHS Foundation Trust | Northwick Park Mental Health Wards - Single Bedrooms Reconfiguration | 520 |
Central and North West London NHS Foundation Trust | Oak Tree Ward - Woodlands Mental Health Wards Reconfiguration, Hillingdon | 502 |
Central and North West London NHS Foundation Trust | Pond Ward - Park Royal Mental Health Wards Reconfiguration | 2,350 |
Croydon Health Services NHS Trust | South West London Acute Providers consolidation of the three procurement functions into a single shared service, purchase to pay system, inventory management, and IT and telephony equipment | 2,149 |
Guy’s and St Thomas’ NHS Foundation Trust | Patient Centric Supply Chain | 10,500 |
Imperial College NHS Trust | The Development of an Endovascular Hybrid Theatre | 1,865 |
Kingston NHS Foundation Trust | Patient Flow Transformation Programme | 3,444 |
London North West University Healthcare NHS Trust | Re-provision of eight compliant theatres | 27,030 |
Moorfields Eye Hospital NHS Foundation Trust | Project Oriel - a new eye care, research and education facility | 18,2481 |
South London and Maudsley Foundation Trust | CAMHS Tier 4. Eight additional beds for people with learning difficulties/autistic spectrum disorders. Beds would open December 2018 | 2,700 |
South West London and St George’s NHS Mental Health Trust | EMP Enabler - New Care Home | 7,100 |
South West London and St George's NHS Mental Health Trust | Barnes Medical Centre development of a healthcare facility to provide mental health outpatient services, an extended range of general practice services, and a range of other community services | 11,100 |
London Ambulance Service | Addition of 25 Double Crewed Ambulance vehicles is expected to receive all their £3,849,000 funding in 2018-19. | 3,8492 |
Notes:
1Further funding is beyond the period to 2022-23 and contributions will also be from other funding sources. Part of the Camden and Islington funding is in the form of a bridging loan in advance of land disposal receipts.
2All funding for this scheme expected to be provided in 2018-19.
In addition, future funding has been allocated for some large capital schemes to specific London providers and as follows:
University College London Hospitals NHS Foundation Trust
- there remains around £52.6 million available which was allocated specifically for the introduction of proton beam therapy; and
- there remains around £96.9 million available for the ongoing development of the haematology and short stay surgery, and head and neck services.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much capital funding has been approved by his Department for Barking, Havering and Redbridge Universities NHS Trust in each year since 2010.
Answered by Stephen Hammond
The attached table shows the capital funding allocated to each National Health Service trust in London, including Barking, Havering and Redbridge Universities NHS Trust, in each financial year from 2010-11 to 2017-18 inclusive.
Due to the way in which some funding was recorded in 2010-11 and 2011-12, it has not been possible to separate revenue and capital funding. Because of this, some funding has been excluded from this table for these years and is shown by an asterisk.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much capital funding his Department has allocated to each NHS trust in London in each year since 2010.
Answered by Stephen Hammond
The attached table shows the capital funding allocated to each National Health Service trust in London, including Barking, Havering and Redbridge Universities NHS Trust, in each financial year from 2010-11 to 2017-18 inclusive.
Due to the way in which some funding was recorded in 2010-11 and 2011-12, it has not been possible to separate revenue and capital funding. Because of this, some funding has been excluded from this table for these years and is shown by an asterisk.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to increase investment to meet social care needs in north-east London.
Answered by Caroline Dinenage
Social care funding for future years will be settled in the Spending Review, where the overall approach to funding local government will be considered in the round.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he plans to ensure more effective regulation of providers of cosmetic laser treatments; and whether it is his policy to introdude a register of such providers.
Answered by Dan Poulter
On 24 April 2013, the independent Review of the Regulation of Cosmetic Interventions, chaired by Sir Bruce Keogh, was published. A copy has already been placed in the Library.
The Government Response to the Review of the Regulation of Cosmetic Interventions, was published on 13 February. A copy of the response has already been placed in the Library. We fully accept the principles of the Keogh review and the overwhelming majority of the recommendations.
The Government has undertaken to strengthen standards through better training and robust qualifications, and explore how far supervision from regulated professionals might support self-regulation of the sector.
The Royal College of Surgeons has set up an inter-specialty committee to ensure standards for cosmetic surgery and will work with the General Medical Council on a code of ethical conduct. Health Education England (HEE) is leading on a review of training and qualifications for providers of non-surgical cosmetic interventions, including lasers. On 11 September, HEE published a phase 1 report Review of qualifications required for delivery of non-surgical cosmetic interventions. A copy of the report is attached.
The Care Quality Commission has developed a new inspection methodology to cover independent health providers, reflecting the protocols used for National Health Service hospitals. The inspections will be conducted with relevant specialists within the inspection teams, including those with experience in cosmetic interventions.
The Department is also taking steps to meet relevant stakeholders to discuss cosmetic procedures and the necessity and form of any further regulation to protect the public. There are no current plans to introduce a statutory register of providers of cosmetic laser treatments.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to improve pancreatic cancer survival rates.
Answered by Jane Ellison
Achieving earlier diagnosis of cancer is key to our ambition to save an additional 5,000 lives per year by 2014-15. However, we know that early diagnosis of pancreatic cancer can be very difficult as the symptoms are shared with a wide range of benign conditions.
The National Institute for Health and Care Excellence (NICE) Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners (GPs) assess when it is appropriate to refer patients for suspected cancer, including pancreatic cancer. NICE is in the process of updating the guidelines to ensure that these reflect latest evidence and can continue to support GPs to identify patients with suspected cancer symptoms and urgently refer them as appropriate. NICE's anticipated publication date for the revised guidelines is May 2015.
The cancer waiting times two week urgent suspected cancer standard – which is included in the NHS Constitution – ensures that, where GPs are concerned that a patient might have cancer, they are seen quickly by secondary care.
In 2013, Macmillan Cancer Support, partly funded by the Department, piloted an electronic cancer decision support tool for GPs to use in their routine practice.
The tool covered pancreatic cancers and was designed to help GPs identify patients whom they might not otherwise refer urgently for suspected cancer. Over 400 GP practices across England participated in the pilot. A full evaluation of the pilot is currently being undertaken by Cancer Research UK and the Department's Policy Research Unit and Macmillan Cancer Support is working with GP IT software companies to further develop, promote and disseminate the tool.
At a local level, it is for individual clinical commissioning groups to promote and enhance the diagnostic capability to deliver better outcomes. Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned at the moment by NHS England. NHS England's pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.
NHS England has recently asked NICE to develop a clinical guideline and quality standard on pancreatic cancer. These will complement the existing Improving Outcomes for Upper Gastro-Intestinal Cancers guidance that describes best practice in the delivery of services for patients with all types of upper gastro-intestinal cancer, including pancreatic cancer.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to increase research funding for pancreatic cancer treatments.
Answered by Dan Poulter
The usual practice of the Department's National Institute for Health Research (NIHR) is not to ring-fence funds for expenditure on particular topics: research proposals in all areas compete for the funding available. The NIHR welcomes funding applications for research into any aspect of human health, including pancreatic cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and the National Health Service, value for money and scientific quality.
In August 2011, the Government announced £800 million investment over five years in a series of NIHR Biomedical Research Centres and Units, including £61.5 million funding for the Royal Marsden/Institute of Cancer Research Biomedical Research Centre, and £6.5 million funding for the Liverpool Biomedical Research Unit in gastrointestinal disease (which has a major focus on pancreatic cancer treatment). Some research they conduct is relevant to multiple cancer sites.
Pharmaceutical companies work in partnership with NIHR research infrastructure. The NIHR Clinical Research Network is currently hosting six pancreatic cancer treatment studies that are recruiting patients and have commercial funders. Commercial partners also work with the NIHR Biomedical Research Centres and Units, and with the Experimental Cancer Medicine Centres (jointly funded by NIHR and Cancer Research UK).
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to ensure earlier diagnosis of pancreatic cancer.
Answered by Jane Ellison
Achieving earlier diagnosis of cancer is key to our ambition to save an additional 5,000 lives per year by 2014-15. However, we know that early diagnosis of pancreatic cancer can be very difficult as the symptoms are shared with a wide range of benign conditions.
The National Institute for Health and Care Excellence (NICE) Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners (GPs) assess when it is appropriate to refer patients for suspected cancer, including pancreatic cancer. NICE is in the process of updating the guidelines to ensure that these reflect latest evidence and can continue to support GPs to identify patients with suspected cancer symptoms and urgently refer them as appropriate. NICE's anticipated publication date for the revised guidelines is May 2015.
The cancer waiting times two week urgent suspected cancer standard – which is included in the NHS Constitution – ensures that, where GPs are concerned that a patient might have cancer, they are seen quickly by secondary care.
In 2013, Macmillan Cancer Support, partly funded by the Department, piloted an electronic cancer decision support tool for GPs to use in their routine practice.
The tool covered pancreatic cancers and was designed to help GPs identify patients whom they might not otherwise refer urgently for suspected cancer. Over 400 GP practices across England participated in the pilot. A full evaluation of the pilot is currently being undertaken by Cancer Research UK and the Department's Policy Research Unit and Macmillan Cancer Support is working with GP IT software companies to further develop, promote and disseminate the tool.
At a local level, it is for individual clinical commissioning groups to promote and enhance the diagnostic capability to deliver better outcomes. Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned at the moment by NHS England. NHS England's pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.
NHS England has recently asked NICE to develop a clinical guideline and quality standard on pancreatic cancer. These will complement the existing Improving Outcomes for Upper Gastro-Intestinal Cancers guidance that describes best practice in the delivery of services for patients with all types of upper gastro-intestinal cancer, including pancreatic cancer.
Asked by: Mike Gapes (The Independent Group for Change - Ilford South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to ensure that GPs make earlier referrals in cases of possible pancreatic cancer.
Answered by Jane Ellison
Achieving earlier diagnosis of cancer is key to our ambition to save an additional 5,000 lives per year by 2014-15. However, we know that early diagnosis of pancreatic cancer can be very difficult as the symptoms are shared with a wide range of benign conditions.
The National Institute for Health and Care Excellence (NICE) Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners (GPs) assess when it is appropriate to refer patients for suspected cancer, including pancreatic cancer. NICE is in the process of updating the guidelines to ensure that these reflect latest evidence and can continue to support GPs to identify patients with suspected cancer symptoms and urgently refer them as appropriate. NICE's anticipated publication date for the revised guidelines is May 2015.
The cancer waiting times two week urgent suspected cancer standard – which is included in the NHS Constitution – ensures that, where GPs are concerned that a patient might have cancer, they are seen quickly by secondary care.
In 2013, Macmillan Cancer Support, partly funded by the Department, piloted an electronic cancer decision support tool for GPs to use in their routine practice.
The tool covered pancreatic cancers and was designed to help GPs identify patients whom they might not otherwise refer urgently for suspected cancer. Over 400 GP practices across England participated in the pilot. A full evaluation of the pilot is currently being undertaken by Cancer Research UK and the Department's Policy Research Unit and Macmillan Cancer Support is working with GP IT software companies to further develop, promote and disseminate the tool.
At a local level, it is for individual clinical commissioning groups to promote and enhance the diagnostic capability to deliver better outcomes. Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned at the moment by NHS England. NHS England's pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.
NHS England has recently asked NICE to develop a clinical guideline and quality standard on pancreatic cancer. These will complement the existing Improving Outcomes for Upper Gastro-Intestinal Cancers guidance that describes best practice in the delivery of services for patients with all types of upper gastro-intestinal cancer, including pancreatic cancer.